LifeMD's Valuation and Price Target Story Shifts Amid Q3 Revenue and EBITDA Shortfalls and Increased Competition in Weight Management

LifeMD's fair value estimate is at $9.25 per share, with some analysts adjusting their targets after the company's Q3 revenue and EBITDA shortfall. Firms with Buy ratings, such as H.C. Wainwright, Lake Street, and BTIG, still see upside despite lower targets. Mizuho maintains a Neutral rating and lowers its target to $6 due to increased competition in weight management offerings.